10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?
This biotech stock could soar 30% or more over the next 12 months if some analysts are right.
Overview
With a market cap hovering near $60 billion, Argenx SE (NASDAQ: ARGX) is no longer a new kid on the block in the biopharmaceutical world. However, the drugmaker still has a long way to go before becoming one of the largest healthcare companies.
Quite a few people on Wall Street believe that Argenx will make some headway on that goal in the near future, though. While the biotech stock was priced at roughly $919 as of the market close on Friday, Oct. 2, 2026, 10 analysts predict that it's headed to at least $1,200 over the next 12 months.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- Tyler Perry lists huge Beverly Hills mansion for $57 million: ‘Yep, moving to Puerto Rico’
- Cut spending to curb runaway borrowing costs, Goldman's Gutman tells governments
- The S&P 500 Has Never Been Lower 12 Months After a Midterm Election. Not Once in 19 Tries. Here's Whether 2026 Could Finally Break That Streak.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.